{"schema_version":"secwatch.filing_event.v1","accession":"0001023024-24-000100","form_type":"8-K","ticker":"ANIP","cik":"0001023024","company_name":"ANI PHARMACEUTICALS INC","filed_at":"2024-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.411947+00:00","generated_at":"2026-05-30T02:39:02.182657+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"ANI Pharmaceuticals posts record Q3 revenue of $148.3M, raises 2024 guidance","bullets":["Record quarterly net revenue of $148.3M (+12.5% YoY); Cortrophin Gel revenue $52.6M (+76.8%).","GAAP net loss of $24.2M (-$1.27 diluted EPS) vs net income of $9.5M year ago; adjusted non-GAAP EPS of $1.34.","Completed Alimera acquisition on Sept 16, adding ILUVIEN and YUTIQ; contributed $3.9M revenue in partial quarter.","Raised FY2024 guidance: net rev $594-602M, adjusted EBITDA $149-153M, adjusted EPS $4.90-$5.05.","New capital structure with $316.25M 2.25% convertible notes due 2029; expected to reduce interest expense ~$39M annually."],"urls":{"canonical":"https://secwatch.observer/filing/0001023024-24-000100","json":"https://secwatch.observer/filing/0001023024-24-000100.json","markdown":"https://secwatch.observer/filing/0001023024-24-000100.md","text":"https://secwatch.observer/filing/0001023024-24-000100.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1023024/000102302424000100/0001023024-24-000100-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1023024/000102302424000100/ani-20241108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T02:39:02.182657+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}